All In Biotech

Drug Trial Radar · NCT07652515

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer

Phase 4, Open Label, Single-arm, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Primary Advanced or Recurrent Endometrial Cancer

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 17, 2026

Primary completion

Aug 30, 2030

Study completion Aug 30, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).

Conditions

  • Neoplasms, Endometrial

Interventions

  • DostarlimabDrug

    Dostarlimab will be administered.

  • CarboplatinDrug

    Carboplatin will be administered.

  • PaclitaxelDrug

    Paclitaxel will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49Time frame: Up to Week 49

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.